Statement: Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once.
Primary_evidence: Adverse Events 1:   Total: 10/33 (30.30%)   Constipation 1/33 (3.03%)   Dysphagia 1/33 (3.03%)   Ileus 1/33 (3.03%)   Nausea 1/33 (3.03%)   Vomiting 1/33 (3.03%)   Fatigue 1/33 (3.03%)   Pain 1/33 (3.03%)   Sepsis 2/33 (6.06%)   Urinary tract infection 1/33 (3.03%)   Alanine aminotransferase increased 1/33 (3.03%)   Aspartate aminotransferase increased 1/33 (3.03%)   Dehydration 2/33 (6.06%)